Age Related Macular Degeneration (AMD) Market

Global Age Related Macular Degeneration (AMD) Market Size, Share & Industry Trends Analysis Report By Drug Type (Aflibercept, Ranibizumab and Others), By Disease Type (Wet and Dry), By Distribution Channel, By Regional Outlook and Forecast, 2023 - 2030

Report Id: KBV-16156 Publication Date: July-2023 Number of Pages: 242
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support

Market Report Description

The Global Age Related Macular Degeneration (AMD) Market size is expected to reach $13.9 billion by 2030, rising at a market growth of 5.4% CAGR during the forecast period.

The steep rise in per-capita healthcare spending, in addition to the rising public demand for high- quality, inexpensive healthcare services, is driving the growth of healthcare products, therefore, hospital pharmacy would generate more than 55% share of the market by 2030. The increasing number & size of investments invested in the healthcare industry by governments of different nations is one of the primary drivers of the market’s growth. The WHO reports that healthcare spending reached a record high of US $9 trillion (about 11% of global GDP) due to substantial increases in healthcare spending by governments at all income levels. In general, rising government health spending largely offsets declining personal spending. Increasing spending in the healthcare industry has led to an increase in market innovations. Some of the factors impacting the market are increase in elderly population, growing awareness of AMD, and Wet AMD drugs' adverse effects.

Age Related Macular Degeneration (AMD) Market Size - Global Opportunities and Trends Analysis Report 2019-2030

As it gets worse with time, vision loss in the elderly is a major issue. The two main types of macula deterioration are wet and dry macular degeneration. Both are possibly fatal and require medical care. According to the WHO, there will be 1.4 billion people aged 60 and older by 2050, up from the current 1 billion. The number of individuals 60 and older worldwide will double (to 2.1 billion) by 2050. Some key players are working on vitreous implants and longer-acting anti-VEGFs that enable sustained medication delivery. Additionally, the most frequent cause of permanent vision loss is macular degeneration. To make the public aware of the effects of AMD and the best treatment options, NGOs, optometrist groups, and health agencies run various programs, activities, and campaigns. The National AMD Awareness Month celebrated in February and strives to increase awareness of AMD as the main cause of visual loss, is one such significant initiative. Rising financing for the condition's research and related activities, which also encourage people to have eye exams to improve the likelihood of early identification, is another factor driving the need for macular degeneration drugs.

However, wet AMD medicines' wide range of negative effects constrains the market's growth. Growth is expected to be restricted by side effects such as retinal vasculitis, intraocular inflammation, concomitant vascular occlusion, nausea, vomiting, stopping loss of vision in 90% of cases, bleeding in the eye, redness & irritation of the eye, and individuals losing their vision permanently. High blood pressure and inflammation of the nose and throat are also prevalent. Furthermore, these medications are injected directly into the eye, which carries potential hazards. These issues may hamper market expansion. Moreover, as the COVID-19 pandemic had significant effects on healthcare systems globally, including the treatment and management of chronic diseases like age-related macular degeneration (AMD), it had a negative impact on the age-related degeneration (AMD) market. Due to clinic closures and reduced hospital capacity during the outbreak, many people could not get basic eye care and treatment. However, the pandemic impacted the development and approval of new treatments for age-related macular degeneration (AMD), which has had a negative effect on the expanding AMD market.

Drug Type Outlook

On the basis of drug type, the market is segmented into aflibercept, ranibizumab, and others. In 2022, the aflibercept segment dominated the market with the maximum revenue share. This segment will expand due to the increased use of the medicine Aflibercept globally and the rise in age-related macular degeneration (AMD) among the older population.

Disease Type Outlook

Based on diseases type, the market is classified into wet, and dry. The dry segment garnered a significant revenue share in the market in 2022. Dry AMD causes 85 to 90% of all cases of macular degeneration. Vitamin formulations are the only treatment options for dry macular degeneration. Luminate, Zimura, and intravitreal pegcetacoplan are only a few of the cutting-edge therapeutic approaches for its treatment that are now being tested in clinical settings. Accepting these candidates could accelerate the dry AMD segment's expansion in the upcoming years.

Age Related Macular Degeneration (AMD) Market Share and Industry Analysis Report 2022

Distribution Channel Outlook

By distribution channel, the market is categorized into hospital pharmacy, retail pharmacy, and online pharmacy. The online segment recorded a remarkable revenue share in the market in 2022. The segment's growth is primarily driven by rising internet usage, the digitization of healthcare services, and an increase in tech-savvy consumers worldwide. Consumers' desire for online shopping, which is increasingly centered on convenience, is also a factor in the increase.

Age Related Macular Degeneration (AMD) Market Report Coverage
Report Attribute Details
Market size value in 2022 USD 9.2 Billion
Market size forecast in 2030 USD 13.9 Billion
Base Year 2022
Historical Period 2019 to 2021
Forecast Period 2023 to 2030
Revenue Growth Rate CAGR of 5.4% from 2023 to 2030
Number of Pages 242
Number of Table 340
Report coverage Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies Strategic Developments, Company Profiling
Segments covered Drug Type, Disease Type, Distribution Channel, Region
Country scope US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria
Growth Drivers
  • Increase in elderly population fuels cases of age-related eye disease
  • Rising healthcare expenditure and government support
  • Wet AMD drugs' adverse effects

Regional Outlook

Region wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The Asia Pacific region covered a considerable revenue share in the market in 2022. The sale of medications for exudative AMD is now very low in APAC because of problems with accessibility and expensive prescriptions. However, AMD is highly prevalent in this region, making it a potentially growing market. A few companies in APAC are also involved in the marketing and research of exudative AMD therapies. In addition, the demand for wet age-related macular degeneration drugs is expected to rise considerably in the coming years due to the region accounting for more than a third of all age-related macular degeneration cases globally.

Free Valuable Insights: Global Age Related Macular Degeneration (AMD) Market size to reach USD 13.9 Billion by 2030

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Biogen, Inc., Bayer AG, Apellis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Ionis Pharmaceuticals, Inc., Novartis AG, Sanofi S.A., Coherus Biosciences, Inc. and Bausch Health Companies, Inc.

Strategies deployed in the Market

  • Jun-2023: Bausch + Lomb introduced PreserVision AREDS 2 Formula soft gels plus coenzyme Q10 (CoQ10) in the United States. It is the only eye vitamin that combines the precise nutrient formula advised by the National Eye Institute (NEI) to help reduce the risk of moderate to advanced Age-related Macular Degeneration (AMD) progression in AMD patients with CoQ10 to support heart health.
  • Feb-2023: Apellis Pharmaceuticals received approval from the U.S. Food & Drug Administration (FDA) for SYFOVRE™ (pegcetacoplan injection). This injection is launched for people with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
  • Aug-2022: Coherus BioSciences announced that the U.S. Food and Drug Administration (FDA) approved CIMERLITM (ranibizumab-eqrn) as a biosimilar product interchangeable with Lucentis® (ranibizumab injection) for all five indications. This product satisfies all of the FDA's strict requirements for the reference product, including those for quality, safety, and efficacy. The anti-VEGF therapeutic class of biologics, which includes CIMERLITM, has revolutionized how retinal patients can keep or regain eyesight.
  • Jun-2022: Biogen together with Samsung Bioepis Co., Ltd. launched BYOOVIZ™ (ranibizumab-nuna), a biosimilar referencing LUCENTIS® (ranibizumab)i in the United States. The biosimilar has been approved by FDA and it would be utilized for the treatment of macular edema following retinal vein occlusion, neovascular (wet) age-related macular degeneration (AMD), and myopic choroidal neovascularization. This is an affordable treatment option for patients suffering from retinal vascular disorders.
  • Feb-2022: Novartis completed the acquisition of Gyroscope Therapeutics, a clinical-stage gene therapy company. With this acquisition, Novartis would take another step toward its goal of providing ophthalmic innovation to treat and prevent blindness globally. The acquisition strengthened its current expertise in retinal disorders and gene therapy.
  • Oct-2020: Novartis took over Vedere Bio, a growing pharmaceutical company. The acquisition strengthened Novartis' dedication to cell and gene therapy and helped Novartis accelerate its efforts to provide revolutionary treatments to a variety of patients with blinding conditions. Additionally, the acquisition increased Novartis' presence in ophthalmology and strengthened its position as a global leader in AAV-based gene therapy.
  • Oct-2019: Novartis got the U.S. Food and Drug Administration approval for Beovu® (brolucizumab) injection, also known as RTH258. This injection would be utilized in the treatment of wet age-related macular degeneration (AMD). Beovu is the only anti-VEGF licensed by the FDA to provide both better fluid resolution compared to aflibercept and the capacity to keep eligible wet AMD patients on a three-month dosage interval immediately following a three-month loading phase with uncompromised efficacy.

Scope of the Study

Market Segments Covered in the Report:

By Drug Type

  • Aflibercept
  • Ranibizumab
  • Others

By Disease Type

  • Wet
  • Dry

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

  • Biogen, Inc.
  • Bayer AG
  • Apellis Pharmaceuticals, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • F.Hoffmann-La Roche Ltd.
  • Ionis Pharmaceuticals, Inc.
  • Novartis AG
  • Sanofi S.A.
  • Coherus Biosciences, Inc.
  • Bausch Health Companies, Inc.
Need a report that reflects how COVID-19 has impacted this market and its growth? Download Free Sample Now

Frequently Asked Questions About This Report

This Market size is expected to reach $13.9 billion by 2030.

Rising healthcare expenditure and government support are driving the Market in coming years, however, Wet AMD drugs' adverse effects restraints the growth of the Market.

Biogen, Inc., Bayer AG, Apellis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Ionis Pharmaceuticals, Inc., Novartis AG, Sanofi S.A., Coherus Biosciences, Inc. and Bausch Health Companies, Inc.

The Wet segment is leading the Market by Disease Type in 2022; thereby, achieving a market value of $11.9 billion by 2030.

The North America region dominated the Market by Region in 2022; thereby, achieving a market value of $6.3 billion by 2030.



Call: +1(646) 600-5072


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo